Daré Bioscience, Inc. (NASDAQ:DARE): Q1 Earnings Show Revenue Beat Amidst Pipeline Progress in Women's Health

Font: Financial Modeling Prep  • May 15, 2026

• Strong Q1 Revenue Performance: Daré Bioscience significantly exceeded revenue forecasts, reporting $152,455.00 against an estimated $27,000.00.
• Strategic Pipeline Development: The company is advancing key products like Ovaprene® and preparing for the commercial launch of Flora Sync LF5™ in summer 2026, aiming for first product revenue in June.
• Financial Health Indicators: Despite the revenue beat, the company reported a negative EPS of -$0.21 and a negative P/E ratio of -3.46, alongside a debt-to-equity ratio of 2.20 and a current ratio of 1.03, reflecting its clinical-stage investment phase.

Daré Bioscience, Inc. (NASDAQ:DARE) is a clinical-stage biopharmaceutical company dedicated to advancing innovative products for women's health. This biotech firm actively develops therapies for contraception, vaginal health, and other critical areas. A key product in its robust pipeline is Ovaprene®, an investigational hormone-free monthly contraceptive, which holds the potential to be a first-in-category product if approved.

On May 14, 2026, Daré Bioscience reported its first-quarter earnings results. The company announced an earnings per share (EPS) of -$0.21, which significantly surpassed the analyst consensus estimate of -$0.33. EPS, a crucial metric in stock analysis, illustrates the profit a company generates per share of its stock. A negative EPS typically indicates that the company is not yet profitable, a common stage for clinical-stage biopharmaceutical companies.

The company also reported robust quarterly revenue of $152,455.00, which was significantly higher than the forecast of $27,000.00. This strong financial performance comes as Daré Bioscience prepares for the commercial launch of Flora Sync LF5™ in the summer of 2026. As highlighted by GlobeNewswire, the company anticipates generating its first product revenue from this launch in June 2026, marking a significant milestone for the biotech stock.

Despite the impressive revenue beat, Daré Bioscience's financial metrics indicate it is not currently profitable, reflected by a negative price-to-earnings (P/E) ratio of -3.46. The P/E ratio is a key valuation metric that compares a company's stock price to its earnings. A negative P/E is often observed in companies, particularly in the biopharmaceutical sector, that are investing heavily in research and development before their innovative products reach the market and generate substantial earnings.

Further examining the company's financial health reveals a debt-to-equity ratio of 2.20, indicating a reliance on debt financing over equity to fund its assets. Its current ratio stands at 1.03. This liquidity ratio suggests that Daré Bioscience's short-term assets are just sufficient to cover its short-term debts, pointing to a tight liquidity position as it continues its development phase.